diabetestalk.net

No More Finger Prick. New Technology May Help With Diabetes Management.

No More Finger Prick. New Technology May Help with Diabetes Management.

No More Finger Prick. New Technology May Help with Diabetes Management.

Type 1 and type 2 diabetes technology and medications have come a long way since the invention of insulin in 1921.
But day-to-day management still requires countless finger pricks to draw blood and measure glucose levels.
FreeStyle Libre Flash Glucose Monitoring System, manufactured by Abbott Diabetes Care Inc. and officially approved on September 27 by the U.S. Food and Drug Administration (FDA), strives to be a true game-changer for people with diabetes.
Unlike the Dexcom or Medtronic’s Guardian and Enlite continuous glucose monitors (CGM), which require a minimum of twice-daily finger pricks to calibrate the CGM’s readings with that of a traditional blood glucometer, the Libre system requires zero calibration.
The technology is still similar in that the Libre also uses a small sensor wire that a patient inserts into their subcutaneous tissue.
This sensor measures glucose levels in the interstitial (body fat) fluid versus glucose in the bloodstream.
How the device works
Where the technology continues to differ greatly is in how the glucose levels measured by the sensor wire are then reported to the person using it.
From the get-go, the Libre requires a lengthy 12-hour startup period before the sensor is able to measure and report glucose levels while the Dexcom and Medtronic sensors startup window is a mere two hours.
The most significant difference between these technologies is that the Libre isn’t “continuous.”
When a patient wants to measure their blood glucose level, the Libre requires them to wave a small handheld “mobile reader” over the part of the bo Continue reading

Rate this article
Total 1 ratings
Is Going Organic the Way to Go?

Is Going Organic the Way to Go?

As a person with diabetes, you’ve most likely given some thought to what you choose to eat. Perhaps you’re counting carbohydrates or following a tailored eating plan; maybe you’re careful to make heart-healthy food choices or are trying to incorporate more fruits and vegetables into your diet to help you lose weight. Whatever nutritional path you’ve headed down, undoubtedly you’ve noticed the ever-growing availability of organic foods.
Years ago, the term “organic” may have conjured up images of people with long hair eating bowls of granola or tofu and brown rice purchased at a health-food store. Things are different today.
Organic foods can be found right in your local grocery store and even in the closest Wal-Mart. And not all organic products are necessarily what you’d expect, either. Beer, wine, vodka, cosmetics, and even clothing are now all available in organic versions.
The decision whether to buy, say, organic bananas rather than regular bananas often boils down to the price. According to an article in Consumer Reports in 2006, almost two-thirds of US consumers bought organic foods and beverages in 2005, which was up from approximately half of consumers in 2004. Organic products are part of a fast-growing industry.
What do the terms mean?
Organic foods in the United States are regulated by US Department of Agriculture (USDA). Since 2002, national standards have been implemented to help consumers make informed decisions when buying organic foods. This stemmed from the Organic Foods Production Act passed by Congress in 1990, which charged the USDA with Continue reading

'Clear promise': Diabetes drug reversed memory loss in mice with Alzheimer's, researchers find

'Clear promise': Diabetes drug reversed memory loss in mice with Alzheimer's, researchers find

A team of Chinese and British researchers has discovered that a drug originally created to treat diabetes shows “clear promise” as a treatment for Alzheimer’s disease, since it significantly reversed memory loss in mice.
News of the potential breakthrough was published this week in Brain Research.
“[The drug shows a] clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer's disease," the scientists’ report reads.
“The drug improved memory formation in a mouse model of Alzheimer’s disease,” they said, adding that amyloid plaque load, inflammation and oxidative stress were all visibly reduced.
The new diabetes drug is a triple receptor that combines GLP-1, GIP and Glucagon, three biological molecules known as “growth factors.”
According to Newsweek, researchers tested the receptor in mice specifically created to express certain genes associated with Alzheimer's disease in humans and waited for them to age for a couple of months and sustain some brain damage.
Once given the drug, the mice were put through a maze test and results showed a clear improvement in their learning and memory formation.
"These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro-protective effects in several studies," said lead researcher Christian Holscher said, in a press release from Lancaster University.
The drug improved memory formation in a mouse model of Alzheimer’s disease
- Chinese and British r Continue reading

Diabetes drug found to reverse symptoms of memory loss in Alzheimer's mice

Diabetes drug found to reverse symptoms of memory loss in Alzheimer's mice

The fascinating connection between diabetes and Alzheimer's disease has been studied for several years, with some scientists going so far as to suggest the two conditions are different stages of the same disease. A team of researchers has now discovered that a drug initially developed to treat type 2 diabetes has "significantly reversed memory loss" in early animal trials.
The new research led by Professor Christian Holscher of Lancaster University looked at the neuro-protective effects of a novel diabetes drug called a triple receptor agonist. This drug was initially designed to treat type 2 diabetes by activating GLP-1, GIP and Glucagon growth factor receptors in the brain.
The less time you spend thinking about your cargo, the more time you can spend running your busin...
The study used transgenic mice engineered to express the same mutated genes that cause Alzheimer's in humans. After exposure to the triple receptor agonist the mice displayed significant improvements in a maze-based memory test and reductions in chronic inflammation, oxidative stress and amyloid plaques in the brain.
Past research has already confirmed that single agonist drugs developed for diabetes display neuroprotective effects in animal models, but this is the first time that a triple receptor drug has been studied for these effects. Professor Holscher sees clear promise in these results, and while more research needs to be done, this does point to a potential new treatment for those suffering from Alzheimer's disease.
"Here we show that a novel triple receptor drug shows promise as a potential tre Continue reading

Alzheimer's treatment: Diabetes drug holds promise for fighting disease after 'significantly reversing' memory loss

Alzheimer's treatment: Diabetes drug holds promise for fighting disease after 'significantly reversing' memory loss

A drug developed for type 2 diabetes significantly reverses memory loss and could have potential as a new treatment for Alzheimer’s disease and other neurodegenerative diseases, scientists say.
The study, by UK and Chinese universities, is the first to look at a new combined diabetes drug and found improvements in several characteristic symptoms of Alzheimer’s.
Lead researcher Professor Christian Holscher, from Lancaster University, said these “very promising outcomes” show multi-action drugs developed for type 2 diabetes “consistently show neurological protective effects”.
Independent academics said a reduction in nerve-cell-killing protein molecules was particularly interesting and this was likely to be another avenue in the search for an elusive drug to combat dementia.
He has previously reported optimistic findings from an older diabetes drug, liraglutide, and clinical trials in humans are currently under way.
This latest study, published in the journal Brain Research, looked at a “triple action” treatment that combine three different drugs for type 2 diabetes, acting on biological pathways that could also have an impact on dementia.
Type 2 diabetes is a known risk factor for Alzhemier’s disease and impaired production of insulin – the hormone that people with diabetes don’t produce sufficiently to control their blood sugar – is linked to brain degeneration.
The identification of this link had a twofold benefit, according to charities.
It opened up new research and drug development opportunities, such as this study.
But it also means that by maki Continue reading

No more pages to load

Popular Articles

Related Articles